Viewing Study NCT02189733


Ignite Creation Date: 2025-12-25 @ 3:08 AM
Ignite Modification Date: 2026-04-22 @ 3:24 AM
Study NCT ID: NCT02189733
Status: COMPLETED
Last Update Posted: 2014-11-14
First Post: 2014-07-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Sponsor: Ablynx, a Sanofi company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module